Amyloid-beta neuroprotection mediated by a targeted antioxidant

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Giordano, Courtney R ^a   Terlecky, Laura J ^a   Bollig Fischer, Aliccia ^a,b   Walton, Paul A ^c   Terlecky, Stanley R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; CELL SURVIVAL; GENE EXPRESSION; GENETICS; HIPPOCAMPUS; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; GENE EXPRESSION; HIPPOCAMPUS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84901044955     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04983     Document Type: Article

References (42)

1. Holtzman, D. M., Mandelkow, E. & Selkoe, D. J. Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2, 1-5 (2012).
2. Selkoe, D. J. Alzheimer's disease. Cold Spring Harb Perspect Biol 3, 1-16 (2011).
3. Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-22 (2012).
4. Klein, W. L. Ab toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochemistry International 41, 345-352 (2002).
5. Saraiva, M. J., Magalhaes, J., Ferreira, N. & Almeida, M. R. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr Med Chem 19, 2304-11 (2012).
6. Polidori, M. C. & Nelles, G. Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer's Disease-Challenges and Perspectives. Curr Pharm Des 20, (Epub ahead of print) (2013).
7. Petersen, R. C. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-88 (2005). (Pubitemid 40958434)
8. Persson, T., Popescu, B. O. & Cedazo-Minguez, A. Oxidative Stress in Alzheimer's Disease: Why Did Antioxidant Therapy Fail? Oxidative Medicine and Cellular Longevity 2014, 1-11 (2014).
9. Brewer, G. J. Why vitamin E therapy fails for treatment of Alzheimer's disease. J Alzheimers Dis 19, 27-30 (2010).
10. Droge, W. Free radicals in the physiological control of cell function. Physiol Rev 82, 47-95 (2002). (Pubitemid 34654215)
11. Hsieh, H.-L. & Yang, C.-M. Role of Redox Signaling in Neuroinflammation and Neurodegenerative Diseases. BioMed Research International 2013, 1-18 (2013).
12. Chance, B. The enzyme-substrate compounds of catalase and peroxides. Nature 161, 914-7 (1948).
13. Vainshtein, B. K., Melik-Adamyan, W. R., Barynin, V. V., Vagin, A. A. & Grebenko, A. I. Three-dimensional structure of the enzyme catalase. Nature 293, 411-2 (1981).
14. Giordano, C. R. et al. A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells. Experimental Cell Research 318, 2014-2021 (2012).
15. Price, M., Terlecky, S. R. & Kessel, D. A role for hydrogen peroxide in the proapoptotic effects of photodynamic therapy. Photochem Photobiol 85, 1491-6 (2009).
16. Young, C. N. et al. Reactive oxygen species in tumor necrosis factor-alphaactivated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 128, 2606-14 (2008).
17. Undyala, V., Terlecky, S. R. & Vander Heide, R. S. Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury. Cardiovasc Pathol 20, 272-80 (2011).
18. Giordano, C. R. & Terlecky, S. R. Peroxisomes, cell senescence, and rates of aging. Biochim Biophys Acta 1822, 1358-62 (2012).
19. Lue, L. F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-62 (1999).
20. McLean, C. A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-6 (1999).
21. Wang, J., Dickson, D. W., Trojanowski, J. Q. & Lee, V. M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158, 328-37 (1999). (Pubitemid 29382824)
22. Brewer, G. J. & Price, P. J. Viable cultured neurons in ambient carbon dioxide and hibernation storage for a month. Neuroreport 7, 1509-12 (1996). (Pubitemid 26281133)
23. Brewer, G. J., Torricelli, J. R., Evege, E. K. & Price, P. J. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35, 567-76 (1993). (Pubitemid 23215708)
24. Koepke, J. I. et al. Restoration of peroxisomal catalase import in amodel of human cellular aging. Traffic 8, 1590-600 (2007). (Pubitemid 47578363)
25. Inestrosa, N. C. et al. Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenicmice model of Alzheimer's disease. J Alzheimers Dis 33, 941-59 (2013).
26. Santos, M. J. et al. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem 280, 41057-68 (2005). (Pubitemid 41780601)
27. Legakis, J. E. et al. Peroxisome senescence in human fibroblasts. Mol Biol Cell 13, 4243-55 (2002). (Pubitemid 35471182)
28. Ivashchenko, O. et al. Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk. Mol Biol Cell 22, 1440-51 (2011).
29. Koepke, J. I., Wood, C. S., Terlecky, L. J., Walton, P. A. & Terlecky, S. R. Progeric effects of catalase inactivation in human cells. Toxicol Appl Pharmacol 232, 99-108 (2008).
30. Wood, C. S. et al. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic 7, 97-107 (2006).
31. Huybrechts, S. J. et al. Peroxisome dynamics in cultured mammalian cells. Traffic 10, 1722-33 (2009).
32. Walton, P. A. & Pizzitelli, M. Effects of peroxisomal catalase inhibition on mitochondrial function. Front Physiol 3, 108, 1-10 (2012).
33. Wang, B. et al. Mitochondria are targets for peroxisome-derived oxidative stress in cultured mammalian cells. Free Radic Biol Med 65, 882-94 (2013).
34. Lovell, M. A., Xie, C. & Markesbery, W. R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51, 1562-6 (1998). (Pubitemid 28565232)
35. Fanelli, F. et al. Age-dependent roles of peroxisomes in the hippocampus of a transgenic mouse model of Alzheimer's disease. Mol Neurodegener 8, 8, 1-19 (2013).
36. Cimini, A. et al. Neuronal response of peroxisomal and peroxisome-related proteins to chronic and acute Abeta injury. Curr Alzheimer Res 6, 238-51 (2009).
37. Kou, J. et al. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 122, 271-83 (2011).
38. Garc. et al. Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. Oxidative Medicine and Cellular Longevity 2013, 1-13 (2013).
39. Xie, H. et al. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. J Neurosci 33, 17042-51 (2013).
40. Hirai, K. et al. Mitochondrial Abnormalities in Alzheimer's Disease. The Journal of Neuroscience 21, 3017-3023 (2001). (Pubitemid 32323483)
41. Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3, 120144, 1-9 (2013).
42. Terlecky, S. R. In vitro analysis of peroxisomal protein import. Curr Protoc Cell Biol Chapter 11, Unit 11. 15. 1-11. 15. 10 (2002).